Showing 1,961 - 1,980 results of 103,901 for search '(( 5 ((((teer decrease) OR (mean decrease))) OR (a decrease)) ) OR ( e point decrease ))', query time: 1.34s Refine Results
  1. 1961

    Loss of Rumi leads to intracellular accumulation and decreased IRS levels of Eys in a temperature dependent manner at the mid-pupal stage. by Amanda R. Haltom (664189)

    Published 2014
    “…White arrowheads mark points of rhabdomere attachment and gaps in Eys. (E,E′) A single ommatidium from a wild-type animal at 55% PD shifted to 30°C during IRS formation. …”
  2. 1962
  3. 1963
  4. 1964
  5. 1965
  6. 1966
  7. 1967
  8. 1968
  9. 1969

    Bortezomib in combination with the PLK1 inhibitor BI 2536 induces a significant downregulation of the total levels and phosphorylation of Bcr-Abl, a decrease of downstream phosphorylated STAT5 and a caspase-dependent cell death in TKIs-resistant and –sensitive K562 cell lines. by Octavian Bucur (470431)

    Published 2013
    “…K562 and K562-R cells were treated with 9nM bortezomib and 8nM BI 2536 for 60h, followed by the detection of Bcr-Abl and phosphorylated STAT5. The combined treatment resulted in a marked decrease of the total levels of Bcr-Abl, which correlates with a decrease in the phosphorylation of the downstream STAT5 protein, in both K562 and K562-R cells. β-Actin was used as an internal loading control. …”
  10. 1970
  11. 1971
  12. 1972
  13. 1973
  14. 1974
  15. 1975

    Image2_A Novel Plant Leaf Patch Absorbed With IL-33 Antibody Decreases Venous Neointimal hyperplasia.TIFF by Boao Xie (11621803)

    Published 2021
    “…IL-33 plays a role in venous neointimal hyperplasia both in humans and rats; neutralization of IL-33 by IL-33 antibody can be a therapeutic method to decrease venous neointimal hyperplasia.…”
  16. 1976

    Image1_A Novel Plant Leaf Patch Absorbed With IL-33 Antibody Decreases Venous Neointimal hyperplasia.TIFF by Boao Xie (11621803)

    Published 2021
    “…IL-33 plays a role in venous neointimal hyperplasia both in humans and rats; neutralization of IL-33 by IL-33 antibody can be a therapeutic method to decrease venous neointimal hyperplasia.…”
  17. 1977
  18. 1978
  19. 1979
  20. 1980